In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade \>/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg/m2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.
Rationale: tTF-NGR targets CD13 present in tumor-associated vasculature and on tumor cells of the majority of STS tissue samples examined; preclinical data on combination of tTF-NGR with anthracyclines and trabectedin; low competition of targeted or immune therapy in soft tissue sarcoma (STS) Investigational Medicinal Product: Patients will receive a dose of the Investigational Medicinal Product (IMP) tTF-NGR determined to be safe within the safety run-in cohort of the study as 1-hour rate-controlled infusion (port central venous access, 0.9 % NaCl ad 100 mL) per day for 2 consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday latest 9 am and on the following day, q d 22 x until disease progression or contraindications against further application. Indication: Unresectable or metastatic STS after failure of anthracycline-containing first line treatment or with contraindications to these drugs; CD13 positivity in central histology (grade \>/= 1+) Primary objective and endpoints: The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered: \- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial. Secondary objectives and endpoints: The secondary objective of the trial is to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic STS after failure of anthracycline-containing first line therapy or with contraindications to these drugs with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. To assess the efficacy, the following measurements will be considered: * Overall response rate (ORR, consisting of CR and PR) * Disease control rate (DCR, consisting of CR, PR, and stable disease (SD) for \>18 weeks) * Median progression-free survival (mPFS) * Median overall survival (mOS) * Overall survival (OS) rate at 12 and 18 months To assess the safety profile of tTF-NGR combined with trabectedin (for the phase II and the phase III parts), the following safety endpoints will be considered: * Adverse Events (AEs) assessment based on CTCAE v.5.0. * Standard laboratory parameters and pharmacokinetics * Physical examination findings including assessment of vital signs * Patient reported outcomes (PRO) Study design: Open label, randomized, controlled study in subjects with metastatic or refractory soft tissue sarcoma. Approx. 150 patients will be screened, 126 evaluable patients are enrolled and parallel assigned in a 1:1 fashion to one of two different arms, as outlined below. Randomization will be stratified into CD13+ grades 1 and 2 versus CD13+ grade 3 and number of chemotherapy regimen before entry on trial: 1 versus \>1. Safety run-in part: Before the randomized phase III part of the study, there was a safety cohort of a minimum of 6 patients obtaining at least 2 cycles each of the combination outlined in arm 2 (see below) to confirm safety of this combination (1.5 mg/m2 trabectedin plus a starting dose of 3 mg/m2 tTF-NGR). The patients were treated in-house and in sequence. In case of dose-limiting toxicity (DLT) in one patient of this cohort, a dosemodification protocol for tTF-NGR to 2 mg/m2 was planned, and in case of further tolerability problems in one patient further deescalations in 0.5 mg/m2 steps of tTF-NGR and/or by a reduction of application days were planned. The safety part of the study is completed and the safe dose of tTF-NGR for the randomized phase III part of the study is 0.5 mg/m2 given on days 2 and 3. Since 6 patients tolerated \>/= 2 cycles of this dose without DLT, DLT should occur in \</= 10 % of the patients treated in arm 2 of the trial. The randomized part of the study is open after approval by the DSMB, Ethics Committee and National Competenent Authority (PEI). Randaomzied Phase III part: ARM 1: Trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application. ARM 2: Patients will receive standard trabectedin according to arm 1 plus t0.5 mg/m2 tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) one days 2 and 3 following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapeter 6.1.4 of the protocol). As the evaluation of the study results is based on an intention-to-treat analysis, all patients after randomization will be part of the efficacy population as evaluated by central iRECIST evaluation after end of study. Therapy in both arms can be given on an out-patient basis. All patients receive best supportive care (BSC) according to institutional guidelines. Anti-cancer activity (iRECIST modification) will be assessed (clinically and imaging) at week 9 and then every 9 weeks (independent from cycle length or number) until confirmed progression by iRECIST (iCPD). Decision on application of next cycle at week 9 will be clinical. Imaging and clinical based decision will follow. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point. Safety assessment will be performed on an ongoing basis during study participation, including standard laboratory assessments. The incidence of AEs will be summarized by severity in all patients with at least one study drug intake. Number of sites, countries and patients: Multicenter, up to 14 active study sites in Germany. 19 patients were treated in the phase II safety part, 126 patients will be randomized in a 1:1 ratio to receive open label Trabectedin (Arm 1) or Trabectedin plus tTF-NGR (Arm 2) in the phase III part. Target population: Patients (18-75 years) with advanced or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs. ARM 1: Standard chemotherapy with Trabectidin (in-label) ARM 2: Test product tTF-NGR added to standard Trabectedin Severity grading: Hematological and chemical laboratory tests, and AEs will be graded based on CTCAE v. 5.0. Duration of Treatment: Patients will be treated in repeated cycles until definite disease progression (iRECIST; Seymour L, Lancet Oncol. 2017) in the absence of other withdrawal criteria, and as long as neither patient nor investigator requests treatment discontinuation. Tumor assessments: Detailed tumor assessment visits (clinical and laboratory examinations) after start of therapy are performed before treatment start, at week 9 (+/- 1 week), followed by every 9 weeks (+/- 1 week, independent from cycle length or number) thereafter. Post-study treatment (treatment with another anti-cancer agent) is according to investigator´s choice, but is recorded in the eCRF. At iCPD (confirmed at next tumor assessment after iUPD) tumor assessments will end, but time of death will be recorded for estimation of OS. In case EOT is not determined by iCPD, tumor assessments will go on after EOT until iCPD. Survival status will be collected also for patients withdrawn from the study until death. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point. Statistical analysis: Safety data of the safety run-in part of the study were evaluated using descriptive statistical methods. In the primary statistical analysis of the randomized phase III part, the primary endpoint progression-free survival (PFS) according to iRECIST as judged by central blinded radiology will be compared between the two randomized treatment groups (Arm 1 versus Arm 2). The primary statistical analysis will include all randomized patients (full analysis set) and will be performed according to the intention-to-treat principle. A stratified log-rank test with stratification according to the randomization will be applied (two-sided significance level 5%, power 80%) that provides confirmatory statistical evidence. The timing of the study will be event-driven. The primary statistical analysis will be performed at the time when 106 events in terms of PFS have been observed in total across both treatment groups. This required number of events results from the following sample size calculation. Based on the observed PFS in previous trials, PFS is expected to be exponential, and the expected median PFS is 4.6 months in the control arm (Arm 1) and 8 months in the experimental arm (Arm 2). The corresponding expected hazard ratio is HR=0.575. In a 36 months enrolment period with a rate of 3-4 patients per month, 126 patients will be recruited and randomized. The drop-out process after randomization is expected to be exponential with an up to 25% cumulative drop-out rate at month 24 (competing with the survival process). Follow-up after the last randomized patient is planned to be 12 months, after which it is expected that the required number of 106 events in terms of PFS will have occurred. The statistical analysis of pre-specified secondary endpoints will be performed with descriptive and inferential statistical methods. Prespecified subgroup analyses will be performed with respect to stratification, L-sarcoma vs. others, FNCLCC grade (2 vs. 3), ECOG performance status (ECOG PS 0 vs. PS 1) and previously obtained Lurbinectedin/Trabectedin versus no such previous exposition. Further exploratory analyses will be performed for other relevant treatment variables (e.g. sex, age, number of treatment cycles). Safety data will be evaluated and summarized descriptively. Withdrawal and patient replacement criteria: The patient can withdraw consent for participation in the study at any time without disadvantages for further treatment or prejudice by the therapeutic team. The investigator can withdraw a patient if, in his or her clinical judgment, it is in the best interest of the patient or if the patient cannot comply with the protocol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
126
Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany
RECRUITINGHELIOS Klinikum Berlin-Buch
Berlin, Germany
RECRUITINGTU Dresden Medizinische Fakultät Carl Gustav Carus
Dresden, Germany
RECRUITINGMedizinische Hochschule Hannover
Hanover, Germany
RECRUITINGUniversitätsklinikum Heidelberg
Heidelberg, Germany
RECRUITINGUniversitätsmedizin Mainz
Mainz, Germany
RECRUITINGKlinikum rechts der Isar der technischen Universität München
München, Germany
RECRUITINGLMU Klinikum
Münich, Germany
RECRUITINGUniversity Hospital Muenster, Germany
Münster, Germany
RECRUITINGEfficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.
The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered: \- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OOR)
To assess the efficacy, the following measurement will be considered: Overall response rate (ORR, consisting of CR and PR)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (DCR)
To assess the efficacy, the following measurement will be considered: \- Disease control rate (DCR, consisting of CR, PR, and stable disease (SD) for \>18 weeks)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mPFS)
To assess the efficacy, the following measurement will be considered: \- Median progression-free survival (mPFS)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mOS)
To assess the efficacy, the following measurement will be considered: \- Median overall survival (mOS)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OS)
To assess the efficacy, the following measurement will be considered: \- Overall survival (OS) rate at 12 and 18 months
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (AE)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Adverse Events (AEs) assessment based on CTCAE v.5.0.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Standard laboratory parameters)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- laboratory parameter: Troponin T hs \[ng/l\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Height)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Height \[m\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Weight)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Weight \[kg\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Body surface)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Body surface area \[m2\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: breathing)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: breathing rate by watching and counting \[breaths per minute\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: consciousness)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: consciousness by talking to the patient
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: heart rate)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: heart rate by pulse \[beats per minute\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: ECOG perfomance status)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: ECOG perfomance status
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (ECG)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- ECG (rythm, puls rate, Vector, P Wave, PQ time, QRS Complex, R progression from V1 to V6, QT Interval, PQ time, QRS time, T wave)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Echocardiography)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Echocardiography (diameters of both atria and left and right cardiac chambers at end-diastolic and end-systolic times \[mm\], ejection fraction \[%\], wall diameters \[mm\])
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PRO)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Patient reported outcomes (PRO) by EORTC QLQ C30 questionnaire
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PK)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- pharmacokinetics: AUC \[ng\*h/ml\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.